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EDITORIAL
The paper by Randrianarivelojosia and colleagues in this issue
of the Journal (p. 47) describes the in vitro susceptibility of
Plasmodium falciparum in Madagascar and the Comoros Union
to three of the commonly used antimalarial drugs in the region
— quinine, mefloquine and cycloguanil (the active metabolite
of proguanil).  Severe malaria in the Comoros Union and in
Madagascar is invariably caused by P. falciparum, as it is in the
rest of sub-Saharan Africa. All of 243 isolates assessed were
sensitive to quinine, the drug recommended throughout the
region for treatment of severe malaria. With regard to the two
chemoprophylactic agents studied, all 67 isolates assessed were
sensitive to cycloguanil and only 1 of 128 isolates was
mefloquine-resistant.  The mefloquine-resistant isolate was 1 of
110 evaluated from Madagascar; none of the 18 isolates from
the Comoros Union was resistant.  The authors argue that their
findings confirm the sensitivity of the parasite to the 3 drugs
most commonly used in their countries for both treatment and
prophylaxis.   They submit, on the basis of their findings, that
current policy for treatment of severe malaria with a 7-day
course of quinine, and prophylaxis with either mefloquine or
cycloguanil-based regimens, is justified by the in vitro
laboratory findings that they have shown.    
These conclusions are interesting and important as malaria
morbidity and mortality is rising.  This is principally a result of
increasing antimalarial resistance, and the results seem
reassuring.1,2 Undoubtedly there are public health benefits to
knowing the drug sensitivity profile of P. falciparum in malaria
endemic areas and to applying such knowledge to guiding
drug policy for malaria case management and prophylaxis of
the disease.   When one considers how antimicrobial sensitivity
testing in vitro has guided antibiotic selection and policies for
many other infectious diseases, it is logical and makes good
sense that a similar approach should be employed for malaria.
The public health benefits of a comprehensive profile being
determined across the African continent of P. falciparum drug
sensitivity and changes in resistance over time by a
collaborating network of competent laboratories would be
considerable.   This, in short, is the importance of the
Antananarivo programme.
However, since Randrianarivelojosia et al. derive several
clear-cut recommendations for the treatment and prevention of
P. falciparum malaria from their findings it is necessary to look
critically at the justification of their claim and the reliability of
their findings. 
As there is little evidence to support the efficacy of proguanil
as a single agent, proguanil is generally only recommended in
combination with chloroquine (in chloroquine-sensitive areas)
or atovaquone (in the fixed-dose combination Malarone). To
conclude that recommendations for prophylaxis are justified, it
is important to consider the efficacy of these widely used
partner drugs, as well as that of cycloguanil. Resistance is
thought to arise from spontaneous chromosomal point
mutations or gene duplications, which are independent of drug
selection pressure. De novo resistance is determined by the
intrinsic frequency with which these point mutations occur,
and the degree of resistance conferred by the change.3 High-
level atovaquone resistance develops by the selection of a
single mutant cytochrome b gene, explaining why resistance
develops so rapidly when atovaquone is used as monotherapy.4
These more resistant parasites have a survival advantage in the
presence of antimalarial drugs.  Several factors encourage the
spread of resistance. They include the proportion of
transmissible malaria infections exposed to sub-therapeutic
drug concentrations, the drug concentration profile (a long
elimination phase favours resistance), the pattern of drug use,
and the level of immunity in the community. Thus, resistance
frequently develops first to the antimalarials most widely used
in the treatment of uncomplicated malaria, particularly
chloroquine and sulfadoxine-pyrimethamine. However, the
treatment policy for uncomplicated malaria in the area is not
addressed by this study. The authors refer to the presence of
chloroquine resistance in the study area, particularly in the
Comoros Union, which is not surprising given its prevalence
across almost all of sub-Saharan Africa. The efficacy of
proguanil (cycloguanil)-based regimens cannot be concluded
from this study alone. 
It is also necessary to consider, in general, how feasible it is
to extrapolate in vitro results to clinical outcome.  As resistance
means that there is a shift to the right in the dose-response
(concentration-effect) relationship, it is to be expected that this
might be reliably quantified in vitro. In vitro studies are not
influenced by partial immunity acquired after repeated 
P. falciparum malaria infections (which do influence the in vivo
response), and in vitro findings would therefore be as relevant
to non-immune travellers, as to semi-immune locals. However,
extrapolation of in vitro results to clinical outcome is not
straightforward, for several reasons.   In the first place, the
authors have set drug concentration levels for each drug, above
which the parasite is regarded as resistant and below which it
is seen as being sensitive.   But these levels are in the main
arbitrary, and not universally agreed upon or in accordance
with those set by others.   Moreover, the results are critically
dependent on precise details of the laboratory method; even
minor changes in methodology might significantly influence
the result.   Unless the methods used for in vitro drug
sensitivity testing are standardised between laboratories,
subjected to robust quality assurance and monitored
accordingly, comparison between laboratories cannot be made
and general inferences that influence policy and clinical
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decisions may not be derived.   There are, in addition,
inescapable limitations to extrapolating in vitro findings to the
clinical situation.  In vitro testing does not allow for drug
behaviour in the body — the absorption, metabolism,
distribution and elimination characteristics that significantly
affect the antimalarial action of drugs.  Nor can it take into
account the complex immune response that takes place in
conjunction with the drug action, including cytokine
production, acute phase reactions, and the contribution of the
spleen to the response in acute malarial infection. These are
particularly important determinants of quinine effectiveness as
quinine binds to acute phase reactants, resulting in a decrease
in free quinine levels with increasing disease severity. This is
one of the reasons for using a loading dose of quinine in severe
malaria.5 Treatment failure from under-dosing and poor
adherence, both widespread reasons for lack of antimalarial
effectiveness, are not captured in either in vitro or in vivo
studies.
For the findings from Antananarivo and the conclusions that
have been derived from them to be persuasive, and for them to
influence policy in their own countries and beyond, more is
required than is reported in their paper.   The drug
concentrations that are set for defining resistance of P.
falciparum would need to be defended against clinical evidence,
and laboratory methodology, quality control and monitoring,
all of which should be robustly applied. The efficacy of partner
drugs used in combination regimens would also have to be
reported, and the in vitro sensitivity of those drugs at greatest
risk of developing resistance as a result of intrinsic mutations
(such as atovaquone) or increased drug pressure (generally
those antimalarials recommended for the treatment of
uncomplicated malaria) should also be assessed. Every detail
of the laboratory method would have to be standardised,
within and between laboratories.  If policy decisions are to be
made from such findings the most important element is to
show that sensitivity profiles are changing over time.   More
general agreement is needed on how in vitro laboratory
findings might be used in deciding on policy change, and in
comparing the situation between countries and regions.   The
World Health Organisation has developed guidelines for the
conduct of in vitro drug sensitivity testing, and the use of the
methodology for deciding policy,6 that need to be followed for
the findings reported in this issue of the Journal to have general
application.   The laboratory approach must be affordable for it
to take root in Africa.  And finally, it should be remembered
that drug resistance of the parasite is not the only explanation
for a failed response in malaria.   
If all these requirements can be met, and only if they can be
met, the work of the Madagascar and Comoros Union scientists
will come to be seen as an important foundational step in
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A mosquito whirs on only two wings. By setting up harmonic
vibrations in the air and in its own thorax, it gets more flaps out of
its wings than its nerves or muscles could sustain alone. (From The
Insects, Life Nature Library, 1964).
